Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis.
Manuel Comabella LopezJaume Sastre-GarrigaPere Carbonell-MirabentNicolás FissoloCarmen TurSunny MalhotraDeborah ParetoFrancesc X AymerichJordi RíoÀlex RoviraMar TintoréXavier MontalbanPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
sNfL can be considered a prognostic biomarker of future long-term disability progression in patients with progressive MS. These data expand the little knowledge existing on the role of sNfL as long-term prognostic biomarker in patients with progressive MS.